Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : A new era for Gilead

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2019 | 11:34am EDT

It's been about three years since Gilead's Research and Development group consolidated its work in inflammation and went into partnership with Galapagos. Our most recent Phase 3 data, presented at the European Congress of Rheumatology (EULAR 2019) has been the culmination of a long period of work at Gilead and, in many ways, represents the start of a new era for the organisation.

Our company ethos has always been to prioritise disease areas with the greatest unmet need, and particularly those where we can contribute significantly by advancing the science. If you look at rheumatoid arthritis for instance, there have been many therapies over the last twenty to thirty years, yet there are still a large number of people whose symptoms aren't resolved. These people may be unable to work or do the things that really matter to them, such as being active with their family or continuing the hobbies they had before their disease progressed.

To meaningfully advance the science in inflammation, it is important to explore clinical challenges in multiple ways, which means we need to be collaborative and to think strategically ahead. In addition to our partnership with Galapagos for example, Gilead is collaborating with Verily Life Sciences LLC, part of Google, who will use their cutting-edge technology to analyse biological samples and clinical disease and treatment response data from patients participating in current and future Gilead clinical trials. The goal is to better understand disease signatures and treatment response in order to guide future drug discovery and development.

Building the team

For us to fulfil our ambition in inflammation, we need to recruit and retain the best people. At the moment we're looking for the right team members across the board, from operations and research, to the medical team, marketing and beyond. If you like working in a dynamic area, where things move fast, but the majority of your activity is working on really interesting science, Gilead is a great place to be.

In my seven years here we've launched eleven medicines and they have all been truly innovative. The greatest thing about working at Gilead is knowing that you're making a difference to patients, and because Gilead is still a relatively small company, you can really feel that you are making a personal impact.

As we enter a new era with our work in inflammation, we've got the benefit of a new leadership team and the opportunity for fresh thinking and new approaches from a diverse, cross-functional team. Patients will always be at the heart of the what, the why, and the how at Gilead. Thinking ahead, it would be amazing to see our team realise the kind of transformational changes for people living with inflammatory disease, as we've done in HIV and liver disease over the past thirty years.

If you share our ambition and want to be part of the Gilead team, please visit our career page here.

This article is written and paid for by Gilead Sciences, Inc.

Biography

Dr Michael Elliott is the Vice President for Medical Affairs Europe, Middle East, Australia & Canada, at Gilead Sciences, Inc. Michael has extensive experience in the pharmaceutical industry. Over the past twenty years, Michael has led global development programmes of early and late stage compounds and has been involved in medicine development, clinical research, as well as medical affairs.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

The post A new era for Gilead appeared first on European Pharmaceutical Review.

© Russell Publishing Limited, 2019. All Rights Reserved., source Trade Journals

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
07/19GILEAD SCIENCES : Murad Ali Shah says his government working hard to contain spr..
AQ
07/19SINDH GOVT ALLOCATES RS 600M TO CONT : CM Sindh
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19GILEAD SCIENCES : Licenses Respiratory and Herpes Antiviral Research Programs Fr..
BU
07/19GILEAD SCIENCES : Sindh govt allocates Rs600m to contain HIV, says Murad
AQ
07/18GILEAD SCIENCES INC : Entry into a Material Definitive Agreement, Financial Stat..
AQ
07/18GILEAD SCIENCES : to Present New Data on HIV Prevention, Treatment and Cure Rese..
BU
07/18GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave the Company
AQ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/17GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
More news
Financials (USD)
Sales 2019 22 022 M
EBIT 2019 11 470 M
Net income 2019 7 013 M
Debt 2019 2 514 M
Yield 2019 3,87%
P/E ratio 2019 11,9x
P/E ratio 2020 11,8x
EV / Sales2019 3,87x
EV / Sales2020 3,54x
Capitalization 82 702 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,65  $
Last Close Price 65,04  $
Spread / Highest target 46,1%
Spread / Average Target 24,0%
Spread / Lowest Target -9,29%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS5.08%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC36.77%11 068
ARRAY BIOPHARMA INC226.25%10 372